Considering that the molecular events leading to TAZ activation in tumors are ill-defined and since TAZ mutations or mutations of its known upstream regulators are relatively rare in cancer, we set out to identify novel regulators of TAZ activity. This evidence concerns the gene WWTR1 and cancer.